Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Drug response prediction in high-risk multiple myeloma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Assessing the miRNA sponge potential of RUNX1T1 in t(8;21) acute myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Risk factors for blood stream infections in multiple myeloma: A population-based study of 1154 patients in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR=2.4 (1.2-4.9, P=0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2-27, P=0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P=0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.

OriginalsprogEngelsk
TidsskriftGene
Vol/bind644
Sider (fra-til)80-86
Antal sider7
ISSN0378-1119
DOI
StatusUdgivet - 20 feb. 2018

ID: 52710787